LPA and atherosclerosis: Global, randomized, double-blind, placebo-controlled trial in 180 participants aged 18–80 years with elevated Lp(a) ≥ 125 nmol/L and high risk of ASCVD. The study evaluates subcutaneous zerlasiran 300 mg every 16 weeks, 300 mg every 24 weeks, or 450 mg every 24 weeks versus placebo, with a 36-week treatment durationPrimary endpoint: time-averaged percent change in Lp(a) from baseline to week 36